Medication info

Dihashita Tablet 50/850 mg

Prescription medicationApproval withdrawn
Ingredient · strength
Sitagliptin Phosphate Hydrate›Strength being verifiedMetformin Hydrochloride›Strength being verified
Manufacturer / importer
Aprogen Pharmaceuticals, Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
56 tablets/PTP
Approval status
Approval withdrawn

MFDS item code 201506651 · Approved 2015.09.21

This product's status changed to Approval withdrawn on 2023.08.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is one tablet of this medicine 50/500 mg twice daily. The dose may be increased to one tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, provided that the following dosage adjustments are made. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Aprogen Pharmaceuticals, Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medicine helps improve blood sugar control in patients with type 2 diabetes. It can be used as a monotherapy when blood sugar control is difficult in combination with diet and exercise. If sufficient effect is not seen with monotherapy of metformin or sitagliptin, or if both medications are being used, this medicine (sitagliptin/metformin combination) can be used to substitute or add to enhance therapeutic effectiveness. Furthermore, if blood sugar control is insufficient when used in combination with sulfonylureas, thiazolidinediones, or insulin, this medication is administered to supplement blood sugar control. It is used in various therapeutic stages to improve blood sugar control.

Dosage and Administration

Adult dosage

The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is one tablet of this medicine 50/500 mg twice daily. The dose may be increased to one tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, provided that the following dosage adjustments are made. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Do not administer to the following patients).

Precautions

This medicine is used for the treatment of diabetes and contains two active ingredients: sitagliptin and metformin. First, sitagliptin can rarely cause serious allergic reactions, so if symptoms such as rash, difficulty breathing, or swelling of the face or lips occur, use should be stopped immediately. It can also cause acute pancreatitis, so if symptoms like abdominal pain, nausea, or vomiting arise, consult a doctor promptly. Metformin can cause rare but life-threatening metabolic disorders called lactic acidosis, so it should not be used in patients with poor kidney function or liver dysfunction. This medicine should not be administered to patients with reduced kidney function, severe infections, heart failure, or acute myocardial infarction, and especially should be temporarily discontinued before and after tests using iodinated contrast media. While taking this medication, there is a risk of hypoglycemia, so it is essential to maintain regular meal times and avoid sudden exercise or alcohol consumption. Additionally, vitamin B12 deficiency may occur, making it important to regularly perform blood tests to monitor the condition. It is advisable not to use this medicine in pregnant or potentially pregnant women, breastfeeding mothers, and children and adolescents under 18 years of age. Elderly patients may have reduced kidney function, so dosage adjustments and regular kidney function tests are necessary. Possible adverse effects during use include diarrhea, nausea, vomiting, headache, upper respiratory infection, and if severe joint pain or skin reactions occur, inform a doctor immediately. In case of overdose, general treatment can be applied and, if necessary, the drug can be removed through blood dialysis. Finally, this medicine may interact with other drugs, so it is important to consult healthcare professionals about all medications being taken, especially when used with drugs affecting kidney function.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 25 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • dermatitis
  • loss of appetite
  • weight loss
  • rash
  • urticaria
  • cutaneous vasculitis
  • acute renal failure
  • dyspnea
  • unstable angina
  • dizziness
  • decreased appetite
  • gastrointestinal disturbances
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly sealed container to prevent air from entering, at a temperature between 1 to 30 degrees Celsius. This helps to maintain its effectiveness and prevent deterioration.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

56 tablets/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.